Background -Inhaled frusemide but not bumetanide, another loop diuretic, reduces bronchial responsiveness to sodium metabisulphite (MBS). To investigate whether the effect of frusemide could be mediated through mechanisms other than Na+/K+/Cl-cotransporter inhibition, the effects of amiloride -an inhibitor of sodium channels in the airway epithelium -and of acetazolamide -a specific inhibitor of carbonic anhydrase -against MBS challenge were studied. Methods -In two separate randomised double blind placebo controlled studies, 10 subjects with mild asthma attended on four separate occasions to inhale 7-5mg amiloride or matched placebo, and 500 mg acetazolamide or placebo, immediately before MBS challenge. The concentration of MBS required to cause a 20% fall in baseline FEVy (PC20) was measured.
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Results -Amiloride and acetazolamide had no effect on baseline FEV1. Amiloride had no effect against MBS challenge, but acetazolamide increased -log PC20 from a mean (SE) of 0-75 (0.09) to 0-98 (0.06) representing a 0 77 (0.24) doubling dose increase. Conclusions -These results suggest that carbonic anhydrase activity in the airways, but not sodium flux, modulates bronchial responsiveness to MBS challenge. The action of frusemide is not likely to involve inhibition of carbonic anhydrase activity.
Because frusemide -but not the more potent loop diuretic bumetanide -inhibits indirect challenges such as MBS and adenosine,5 it seems unlikely that inhibition of the Na+/K+/ 2C1-cotransporter is the underlying mechanism of action of frusemide. Because frusemide has inhibitory effects on carbonic anhydrase activity,' we hypothesised that carbonic anhydrase inhibition with acetazolamide may inhibit the bronchoconstrictor effect of MBS. We also investigated whether modification of sodium fluxes across the apical surface ofthe airway epithelium could be involved. Amiloride is another diuretic which inhibits the diffusion of sodium ions through sodium channels at the apical surface of airway epithelial cells. 7 We therefore studied whether inhaled acetazolamide and amiloride could attenuate the bronchoconstrictor effects of inhaled MBS in asthmatic subjects.
Methods

SUBJECTS
Ten non-smoking subjects with mild asthma (five men) of mean (SE) age 31'3 (3 7) years, 93-1 (4 2)% predicted FEVy (table 1) gave informed consent to participate in this study which was approved by the Royal Brompton Hospital ethics committee. All patients were taking short-acting inhaled j2 adrenergic agonists intermittently for the relief of wheeze, but none were on inhaled steroid therapy. None were smokers. All patients were stable for at least six months before entry to study. (table 2) . Mean -log PC20 after amiloride (0-78 (0 08)) was not significantly altered compared with that after placebo (0-83 (0-07)). However, mean -log PC20 increased significantly from 0 75 (0 09)) after placebo to 0-98 (0 06)) after acetazolamide (figure; p<0.02), representing a 0-77 (0 24) doubling dilution increase.
Discussion
The aim of the study was to determine whether the mechanism of action of frusemide, which has been shown to inhibit bronchoconstrictor responses to indirect challenges, may be related to an effect on sodium transport (through a sodium channel inhibitor) or on carbonic anhydrase activity. Our results suggest that this is unlikely to be occurring through significant alterations in Na+ entry channels at the apical surface of airway epithelial cells because amiloride was not effective in inhibiting MBSinduced bronchoconstriction. By contrast, acetazolamide caused a significant inhibition suggesting that carbonic anhydrase activity may modulate MBS-induced bronchoconstriction.
The dose of amiloride administered was in the same range as that given by App and colleagues who found a significant improvement in mucociliary clearance which occurred within the first 10 minutes and was maintained for a further 30 minutes after inhalation in patients with cystic fibrosis. 8 iloride used would be within that described as possessing inhibitory actions against Na+ absorption,9 although the degree of dilution that occurs at the site of action is difficult to determine. Our data suggest that changes in Na+ transport and in airway hydration are not important mechanisms by which frusemide inhibits bronchoconstrictor challenges and are similar to those recently reported by Baldwin and colleagues.'0 Our results are also in agreement with those of Rodwell et al who showed that inhaled amiloride did not protect against dry air challenge in asthmatic subjects in whom protection is afforded by frusemide." However, the negative results obtained with amiloride must be interpreted in the light of the fact that it was not possible to test higher concentrations of amiloride because of its relative insolubility.
Our studies with acetazolamide demonstrate that carbonic anhydrase inhibition provides some protective effect against MBS challenge. The dose of acetazolamide used afforded approximately half the protective effect observed with 40 mg of inhaled frusemide.'2 We used the maximum concentration of acetazolamide that could be maintained in solution and acetazolamide is a very potent inhibitor of carbonic anhydase activity in vitro.'3 Frusemide has previously been shown to possess weak carbonic anhydrase inhibitory activity in the renal tubules as judged by its effect on bicarbonate excretion.' However, because frusemide is generally more effective in inhibiting MBS-induced bronchoconstriction than acetazolamide, it is unlikely that the inhibitory effect of frusemide can be ascribed to its relatively weaker effect as an inhibitor of carbonic anhydrase. The inhibitory effect of acetazolamide is not only restricted to MBS challenges because a small but significant protective effect against bronchoconstriction induced by cold dry air challenge has recently been reported. '4 The mechanism by which inhibition of carbonic anhydrase activity may be inhibiting MBS-induced bronchoconstriction in asthmatic patients is not clear. We have recently shown that acetazolamide can inhibit non-adrenergic non-cholinergic contractile responses induced by electrical stimulation in guinea pig bronchial strips by preventing the release of contractile neuropeptides from sensory nerve endings.'5 Acetazolamide is known to inhibit carbonic anhydrase activity in afferent peripheral nerves ofrodents. 6 Although the precise mechanism of MBS-induced bronchoconstriction is not clear, it is possible that a noncholinergic non-adrenergic neural pathway may be involved'7'8 and acetazolamide may inhibit these pathways.
